/CNW/ - HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric...
There was unambigously good news about the company's single commercialized medication.
AMRN earnings call for the period ending December 31, 2023.
The biopharma company announced a big repurchase plan, along with strong preliminary Q4 results.
AMRN earnings call for the period ending September 30, 2023.
The drugmaker announced a major corporate reorganization and a new CEO.
AMRN earnings call for the period ending March 31, 2023.
Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
On CRISPR's (CRSP) first-quarter earnings call, investors will likely focus on its pipeline, especially its lead candidate exa-cel, due to the absence of marketed drugs.